Updated Sep 2, 2026
Upgrade to a paid plan to see AI rating history on the chart.
Complement Inhibitors Market Complement Inhibitors Market Dublin, Sept. 02, 2026 (GLOBE NEWSWIRE) -- The "Complement Inhibitors Market (2nd Edition): Distribut…
Regeneron Pharmaceuticals has outpaced the healthcare sector, and analysts remain moderately optimistic about the stock’s outlook.
The global non-melanoma skin cancer (NMSC) market is growing as basal cell carcinoma and squamous cell carcinoma rates rise due to UV exposure and aging popula…
Regeneron Pharmaceuticals (REGN) is back in focus after the FDA approved Pasatru garetosmab grts for adults with fibrodysplasia ossificans progressiva, followi…
Regeneron Pharmaceuticals (NasdaqGS: REGN) received FDA approval for Pasatru TM (garetosmab grts) to treat adults with fibrodysplasia ossificans progressiva. T…
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE1sampHYkVtU3h1WFJockVucHlkYmNDQjh1NjN1em5QR29PeE10VlpxVXBjQkRrT0VxNW9BU3prRFVXWVVwOWllbHozY2hwUUk0W…
Sanofi's stock trades above key moving averages as Dupixent and new drugs drive growth, while pipeline setbacks and vaccine weakness weigh.
The FDA approved Pasatru, whose generic name is garetosmab, of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for adults with fibrodysplasia ossificans progress…
Not investment advice. Past performance does not guarantee future results. Full disclaimer